Microdosing + Meditation for Healthy Adults
(OMM Trial)

Recruiting in Palo Alto (17 mi)

Overseen ByMatthew Hicks, ND, MS

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: National University of Natural Medicine

No Placebo Group

Approved in 2 jurisdictions

Trial Summary

What is the purpose of this trial?The goal of this clinical trial is to test the feasibility of combining meditation with psilocybin microdosing in healthy adults. The main questions it aims to answer are: 1. Recruitment and retention feasibility 2. Acceptability, Safety and Tolerability 3. Exploratory Measures: 3.1: Explore potential changes in sleep quality and duration, heart rate variability, and other biometric outcomes captured by the Oura Ring (3rd generation). 3.2: Explore potential changes in quality of life scores 3.3: Explore potential differences in altered states of consciousness across groups 3.4: Explore qualitative data collected during sessions and at follow-up to assess satisfaction and receive feedback about the intervention. Every participant will receive the psilocybin microdosing intervention, however, half of the participants will be randomly selected to receive the meditation intervention.

Eligibility Criteria

This trial is for healthy adults interested in combining meditation with psilocybin microdosing. Participants must be willing to use the Oura Ring to monitor biometrics and complete quality of life assessments. Details on specific inclusion or exclusion criteria are not provided.

Inclusion Criteria

I can attend all required study appointments.

I am 21 years old or older.

No more than 100 hours of lifetime meditation experience

+2 more

Exclusion Criteria

I am not taking lithium, antipsychotics, diclofenac, probenecid, or similar drugs that could interact with the study treatment.

Any form of personality disorder

I have uncontrolled high blood pressure or heart disease.

+6 more

Participant Groups

The study tests if it's feasible to combine meditation with psilocybin microdosing. All participants will try microdoses of psilocybin, but only half, chosen randomly, will also practice meditation. The trial measures recruitment success, participant retention, safety, tolerability, and various health outcomes.

2Treatment groups

Experimental Treatment

Group I: Microdosing plus meditationExperimental Treatment2 Interventions

Group II: Microdosing onlyExperimental Treatment1 Intervention

Psilocybin is already approved in United States, European Union for the following indications:

🇺🇸 Approved in United States as Psilocybin for: